Our network pharmacology analysis, combined with clinical bioinformatics, revealed that Acacetin and Asperglaucide—the pharmacologically active components—interact with PTGS2 and CCND1 in clinical NPC tissue samples. This evidence concerns the gene CCND1 and nasopharyngeal carcinoma.